UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 50

Sortiert nach

Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy

Therapeutic Advances in Medical Oncology, 2023-01, Vol.15, p.17588359231200457-17588359231200457

2023

Volltextzugriff (PDF)

Clinicogenomic Characteristics and Treatment of Young-Onset Colorectal Cancer Patients Treated With Palliative Therapy in Real-World Practice

Cancer control, 2022-04, Vol.29, p.10732748221096842-10732748221096842

2022

Volltextzugriff (PDF)

Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial

Hepatology (Baltimore, Md.), 2023-10, Vol.78 (4), p.E74-E75

2023

Volltextzugriff (PDF)

A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer

Investigational new drugs, 2021-10, Vol.39 (5), p.1335-1347

2021

Volltextzugriff (PDF)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920923424-1758835920923424

2020

Volltextzugriff (PDF)

Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin

Cancers, 2021-01, Vol.13 (2), p.161

2021

Volltextzugriff (PDF)

The Role and Clinical Effectiveness of Multiline Chemotherapy in Advanced Desmoplastic Small Round Cell Tumor

Clinical Medicine Insights. Oncology, 2021, Vol.15, p.1179554920987107

2021

Volltextzugriff (PDF)

Modified Stage Grouping of Diffuse Large B-Cell Lymphoma Involving the Same Side of the Diaphragm in the Rituximab Era

Frontiers in oncology, 2022-05, Vol.12, p.888925-888925

2022

Volltextzugriff (PDF)

Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma

Cancer medicine (Malden, MA), 2021-03, Vol.10 (5), p.1745-1758

2021

Volltextzugriff (PDF)

Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy

European journal of cancer (1990), 2022-11, Vol.176, p.30-40

2022

Volltextzugriff (PDF)

Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients (pts) with cholangiocarcinoma (CCA) before and during adjuvant chemotherapy (ACT): Sub-analysis of the randomized phase 2 STAMP trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4123-4123

2023

Volltextzugriff (PDF)

Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer

European journal of cancer (1990), 2023-09, Vol.191, p.112956-112956, Article 112956

2023

Volltextzugriff (PDF)

Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study

European journal of cancer (1990), 2024-09, Vol.208, p.114194, Article 114194

2024

Volltextzugriff (PDF)

Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial

Hepatology (Baltimore, Md.), 2023-05, Vol.77 (5), p.1540-1549

2023

Volltextzugriff (PDF)

21‐gene expression assay and clinical outcomes of premenopausal patients with hormone receptor‐positive breast cancer

International journal of cancer, 2024-02, Vol.154 (4), p.748-756

2024

Volltextzugriff (PDF)

Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma

Blood, 2020-11, Vol.136 (22), p.2548-2556

2020

Volltextzugriff (PDF)

Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4019-4019

2022

Volltextzugriff (PDF)

Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis

Journal of cancer research and clinical oncology, 2023-07, Vol.149 (8), p.4523-4532

2023

Volltextzugriff (PDF)

Genome-wide copy number alteration (CNA) of circulating cell-free DNA (cfDNA) as a prognostic biomarker in esophageal squamous cell carcinoma (ESCC)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e15582-e15582

2019

Volltextzugriff (PDF)

Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2‐negative metastatic breast cancer

International journal of cancer, 2021-08, Vol.149 (4), p.917-924

2021

Volltextzugriff (PDF)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine (nab-P+GEM) after progression on first-line FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC): Multicenter retrospective analysis

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.689-689

2020

Volltextzugriff (PDF)

Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer; Single-Institution Experience

Cancer Research and Treatment, 2024, 56(3), , pp.774-784

2024

Volltextzugriff (PDF)

Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Cancer research and treatment, 2022-04, Vol.54 (2), p.469-477

2022

Volltextzugriff (PDF)

PP382 EGFR and HER2 exon 20 insertion mutations in non-small cell lung cancer: Clinicogenomic characteristics, diagnosis, and treatment options

ESMO open, 2023-12, Vol.8 (1), p.102175, Article 102175

2023

Volltextzugriff (PDF)

Favorable clinical efficacy of cytotoxic chemotherapy in patients with progressive desmoid tumors: a retrospective real-world study

International journal of clinical oncology, 2024-06, Vol.29 (6), p.853-861

2024

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(50)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(33)
Life Sciences & Biomedicine
(30)
Oncology
(22)
Humans
(17)
Chemotherapy
(10)
Female
(10)
Patients
(9)
Retrospective Studies
(9)
Aged
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Male
(8)
Middle Aged
(8)
Metastases
(7)
Original
(7)
Prognosis
(7)
Survival
(7)
Tumors
(6)
Adult
(5)
Cancer
(5)
Gemcitabine
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy

Clinicogenomic Characteristics and Treatment of Young-Onset Colorectal Cancer Patients Treated With Palliative Therapy in Real-World Practice

Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial

A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis

Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin

The Role and Clinical Effectiveness of Multiline Chemotherapy in Advanced Desmoplastic Small Round Cell Tumor

Modified Stage Grouping of Diffuse Large B-Cell Lymphoma Involving the Same Side of the Diaphragm in the Rituximab Era

Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma

Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy

Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients (pts) with cholangiocarcinoma (CCA) before and during adjuvant chemotherapy (ACT): Sub-analysis of the randomized phase 2 STAMP trial

Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer

Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study

Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial

21‐gene expression assay and clinical outcomes of premenopausal patients with hormone receptor‐positive breast cancer

Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma

Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP)

Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis

Genome-wide copy number alteration (CNA) of circulating cell-free DNA (cfDNA) as a prognostic biomarker in esophageal squamous cell carcinoma (ESCC)

Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2‐negative metastatic breast cancer

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine (nab-P+GEM) after progression on first-line FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC): Multicenter retrospective analysis

Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer; Single-Institution Experience

Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

PP382 EGFR and HER2 exon 20 insertion mutations in non-small cell lung cancer: Clinicogenomic characteristics, diagnosis, and treatment options

Favorable clinical efficacy of cytotoxic chemotherapy in patients with progressive desmoid tumors: a retrospective real-world study

Suchergebnisse filtern